In Silico tool for predicting, designing and scanning IL-2 inducing peptides

Interleukin-2 (IL-2) based immunotherapy has been approved for treating certain types of cancer, as IL-2 plays a crucial role in regulating the immune system. In this study, we developed a method for predicting IL-2-inducing peptides. Our method was trained, tested, and validated on a main dataset containing 6,574 experimentally validated Major histocompatibility complex (MHC) binders, including 3,429 IL-2-inducing and 3,145 non-inducing peptides. A primary analysis of IL-2 inducing and non-inducing peptides revealed that certain residues, such as alanine and leucine, are more abundant in IL-2-inducing peptides. Initially, we developed alignment-based methods, which demonstrated high precision but limited coverage. Subsequently, we developed artificial intelligence-based models, including machine learning (ML), deep learning (DL), and large language models (LLM), to predict IL-2-inducing peptides. Our Extra Tree-based model, developed using dipeptide composition and peptide length, achieved a maximum AUC of 0.82. Finally, we constructed ensemble models that combined artificial intelligence and alignment-based methods. Our best ensemble model, which integrates the Extra Tree-based model with MERCI, achieved the highest AUC of 0.84 and an MCC of 0.51 on the main dataset. One limitation of the main dataset is that both IL-2-inducing and non-inducing peptides are MHC binders. To address this limitation, we created two additional datasets: Alternate Dataset 1, consisting of 3,429 IL-2-inducing peptides and 3,429 non-inducing peptides (MHC non-binders), and Alternate Dataset 2, consisting of 3,429 IL-2-inducing peptides and 3,439 non-inducing peptides (MHC binders + MHC non-binders). Our best ensemble model achieved AUCs of 0.9 and 0.8 with MCCs of 0.61 and 0.44 on Alternate Datasets 1 and 2, respectively. To assist the scientific community, we have integrated the best models from this study into a standalone software and web server, IL2pred, which enables users to predict, scan, and design IL-2-inducing peptides ( https://webs.iiitd.edu.in/raghava/il2pred/ ).

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-07-16
DOI
https://doi.org/10.1038/s41598-025-08388-2
Citations
3
Primary Topic
vaccines and immunoinformatics approaches
Type
article
Field-Weighted Citation Impact
2.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Silico tool for predicting, designing and scanning IL-2 inducing peptides

Dilraj Kaur, Gajendra P. S. Raghava, Anjali Lathwal, Rajesh Kumar et al.
3 citations
Scientific Reports
vaccines and immunoinformatics approaches
2.42
article

In Silico tool for predicting, designing and scanning IL-2 inducing peptides

Dilraj Kaur, Gajendra P. S. Raghava, Anjali Lathwal, Rajesh Kumar, Naman Kumar Mehta
article en
3 citations

Abstract

Interleukin-2 (IL-2) based immunotherapy has been approved for treating certain types of cancer, as IL-2 plays a crucial role in regulating the immune system. In this study, we developed a method for predicting IL-2-inducing peptides. Our method was trained, tested, and validated on a main dataset containing 6,574 experimentally validated Major histocompatibility complex (MHC) binders, including 3,429 IL-2-inducing and 3,145 non-inducing peptides. A primary analysis of IL-2 inducing and non-inducing peptides revealed that certain residues, such as alanine and leucine, are more abundant in IL-2-inducing peptides. Initially, we developed alignment-based methods, which demonstrated high precision but limited coverage. Subsequently, we developed artificial intelligence-based models, including machine learning (ML), deep learning (DL), and large language models (LLM), to predict IL-2-inducing peptides. Our Extra Tree-based model, developed using dipeptide composition and peptide length, achieved a maximum AUC of 0.82. Finally, we constructed ensemble models that combined artificial intelligence and alignment-based methods. Our best ensemble model, which integrates the Extra Tree-based model with MERCI, achieved the highest AUC of 0.84 and an MCC of 0.51 on the main dataset. One limitation of the main dataset is that both IL-2-inducing and non-inducing peptides are MHC binders. To address this limitation, we created two additional datasets: Alternate Dataset 1, consisting of 3,429 IL-2-inducing peptides and 3,429 non-inducing peptides (MHC non-binders), and Alternate Dataset 2, consisting of 3,429 IL-2-inducing peptides and 3,439 non-inducing peptides (MHC binders + MHC non-binders). Our best ensemble model achieved AUCs of 0.9 and 0.8 with MCCs of 0.61 and 0.44 on Alternate Datasets 1 and 2, respectively. To assist the scientific community, we have integrated the best models from this study into a standalone software and web server, IL2pred, which enables users to predict, scan, and design IL-2-inducing peptides ( https://webs.iiitd.edu.in/raghava/il2pred/ ).

Scientific ReportsVol. 15(1)
Indraprastha Institute of Information Technology Delhi (IN), Institute of Cancer Research (GB), Cancer Research UK (GB), National Cancer Institute (US), Indira Gandhi Delhi Technical University for Women (IN), CRUK Lung Cancer Centre of Excellence (GB)
Department of Biotechnology, Ministry of Science and Technology, India, Department of Science and Technology, Ministry of Science and Technology, India, Council of Scientific and Industrial Research, India, University Grants Commission, Indian Institute of Technology Delhi
Openalex Percentile: Top 11%
vaccines and immunoinformatics approaches
2.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.